Hemodynamic effects of morphine and nalbuphine in acute myocardial infarction

Garrett Lee, Reginald Low, Ezra A Amsterdam, Anthony N. DeMaria, Paula W. Huber, Dean T. Mason

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Hemodynamic effects of morphine and the new narcotic analgesic, nalbuphine, were compared in a randomized, double-blind study in 15 patients with acute myocardial infarction (11 men and four women, average age 56.2 yr) and normal group mean hemodvnamic,function. During a 1-hr evaluation the Hmodynamic effects were small but there were changes in several parameters. Morphine reduced heart rate (78 to 72 bpm, p < 0.01) and diastolic and mean arterial pressures (69 to 64 mm Hg, p < 0.05; and 91 to 84 nun Hg, p < 0.05); nalbuphine was associated with a decrease in heart rate (82 to 72 bpm, p < 0.01), decrease in cardiac index, which remained within the normal range (3.16 to 2.75 lminlinz, p < 0.01), and an increase in systemic vascular resistance (1,204 to 1,461 dynes · sec · cm-5 p < 0.05). Neither drug altered systolic arterial pressure, pulmonary artery pressure, pulmonary capillary wedge pressure, stroke index, stroke work index, or pulmonary vascular resistance. Echocardiographic assessment revealed diminution of left ventricular mean velocity gf circumferential fiber shortening sifter nalbuphine (1.26 to 1.08 circlsec, p < 0.05). Both drugs induced small reductions in respiratory rate and arterial pH and increases in PAO2 There were no changes in PaO2. Because of the absence of clinically important deleterious effects on cardiac pump function, nalbuphine merits further investigation as an analgesic in acute myocardial infarction.

Original languageEnglish (US)
Pages (from-to)576-581
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume29
Issue number5
StatePublished - May 1981

Fingerprint

Nalbuphine
Morphine
Hemodynamics
Myocardial Infarction
Vascular Resistance
Arterial Pressure
Heart Rate
Stroke
Pulmonary Wedge Pressure
Narcotics
Respiratory Rate
Double-Blind Method
Pharmaceutical Preparations
Pulmonary Artery
Analgesics
Reference Values
Blood Pressure
Pressure

ASJC Scopus subject areas

  • Pharmacology

Cite this

Hemodynamic effects of morphine and nalbuphine in acute myocardial infarction. / Lee, Garrett; Low, Reginald; Amsterdam, Ezra A; DeMaria, Anthony N.; Huber, Paula W.; Mason, Dean T.

In: Clinical Pharmacology and Therapeutics, Vol. 29, No. 5, 05.1981, p. 576-581.

Research output: Contribution to journalArticle

Lee, Garrett ; Low, Reginald ; Amsterdam, Ezra A ; DeMaria, Anthony N. ; Huber, Paula W. ; Mason, Dean T. / Hemodynamic effects of morphine and nalbuphine in acute myocardial infarction. In: Clinical Pharmacology and Therapeutics. 1981 ; Vol. 29, No. 5. pp. 576-581.
@article{9f69815a1da2404a83e89a287a8064d9,
title = "Hemodynamic effects of morphine and nalbuphine in acute myocardial infarction",
abstract = "Hemodynamic effects of morphine and the new narcotic analgesic, nalbuphine, were compared in a randomized, double-blind study in 15 patients with acute myocardial infarction (11 men and four women, average age 56.2 yr) and normal group mean hemodvnamic,function. During a 1-hr evaluation the Hmodynamic effects were small but there were changes in several parameters. Morphine reduced heart rate (78 to 72 bpm, p < 0.01) and diastolic and mean arterial pressures (69 to 64 mm Hg, p < 0.05; and 91 to 84 nun Hg, p < 0.05); nalbuphine was associated with a decrease in heart rate (82 to 72 bpm, p < 0.01), decrease in cardiac index, which remained within the normal range (3.16 to 2.75 lminlinz, p < 0.01), and an increase in systemic vascular resistance (1,204 to 1,461 dynes · sec · cm-5 p < 0.05). Neither drug altered systolic arterial pressure, pulmonary artery pressure, pulmonary capillary wedge pressure, stroke index, stroke work index, or pulmonary vascular resistance. Echocardiographic assessment revealed diminution of left ventricular mean velocity gf circumferential fiber shortening sifter nalbuphine (1.26 to 1.08 circlsec, p < 0.05). Both drugs induced small reductions in respiratory rate and arterial pH and increases in PAO2 There were no changes in PaO2. Because of the absence of clinically important deleterious effects on cardiac pump function, nalbuphine merits further investigation as an analgesic in acute myocardial infarction.",
author = "Garrett Lee and Reginald Low and Amsterdam, {Ezra A} and DeMaria, {Anthony N.} and Huber, {Paula W.} and Mason, {Dean T.}",
year = "1981",
month = "5",
language = "English (US)",
volume = "29",
pages = "576--581",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Hemodynamic effects of morphine and nalbuphine in acute myocardial infarction

AU - Lee, Garrett

AU - Low, Reginald

AU - Amsterdam, Ezra A

AU - DeMaria, Anthony N.

AU - Huber, Paula W.

AU - Mason, Dean T.

PY - 1981/5

Y1 - 1981/5

N2 - Hemodynamic effects of morphine and the new narcotic analgesic, nalbuphine, were compared in a randomized, double-blind study in 15 patients with acute myocardial infarction (11 men and four women, average age 56.2 yr) and normal group mean hemodvnamic,function. During a 1-hr evaluation the Hmodynamic effects were small but there were changes in several parameters. Morphine reduced heart rate (78 to 72 bpm, p < 0.01) and diastolic and mean arterial pressures (69 to 64 mm Hg, p < 0.05; and 91 to 84 nun Hg, p < 0.05); nalbuphine was associated with a decrease in heart rate (82 to 72 bpm, p < 0.01), decrease in cardiac index, which remained within the normal range (3.16 to 2.75 lminlinz, p < 0.01), and an increase in systemic vascular resistance (1,204 to 1,461 dynes · sec · cm-5 p < 0.05). Neither drug altered systolic arterial pressure, pulmonary artery pressure, pulmonary capillary wedge pressure, stroke index, stroke work index, or pulmonary vascular resistance. Echocardiographic assessment revealed diminution of left ventricular mean velocity gf circumferential fiber shortening sifter nalbuphine (1.26 to 1.08 circlsec, p < 0.05). Both drugs induced small reductions in respiratory rate and arterial pH and increases in PAO2 There were no changes in PaO2. Because of the absence of clinically important deleterious effects on cardiac pump function, nalbuphine merits further investigation as an analgesic in acute myocardial infarction.

AB - Hemodynamic effects of morphine and the new narcotic analgesic, nalbuphine, were compared in a randomized, double-blind study in 15 patients with acute myocardial infarction (11 men and four women, average age 56.2 yr) and normal group mean hemodvnamic,function. During a 1-hr evaluation the Hmodynamic effects were small but there were changes in several parameters. Morphine reduced heart rate (78 to 72 bpm, p < 0.01) and diastolic and mean arterial pressures (69 to 64 mm Hg, p < 0.05; and 91 to 84 nun Hg, p < 0.05); nalbuphine was associated with a decrease in heart rate (82 to 72 bpm, p < 0.01), decrease in cardiac index, which remained within the normal range (3.16 to 2.75 lminlinz, p < 0.01), and an increase in systemic vascular resistance (1,204 to 1,461 dynes · sec · cm-5 p < 0.05). Neither drug altered systolic arterial pressure, pulmonary artery pressure, pulmonary capillary wedge pressure, stroke index, stroke work index, or pulmonary vascular resistance. Echocardiographic assessment revealed diminution of left ventricular mean velocity gf circumferential fiber shortening sifter nalbuphine (1.26 to 1.08 circlsec, p < 0.05). Both drugs induced small reductions in respiratory rate and arterial pH and increases in PAO2 There were no changes in PaO2. Because of the absence of clinically important deleterious effects on cardiac pump function, nalbuphine merits further investigation as an analgesic in acute myocardial infarction.

UR - http://www.scopus.com/inward/record.url?scp=0019409412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019409412&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 576

EP - 581

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -